Technical Analysis for ENTO - Entero Therapeutics Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.40 | -1.74% | -0.01 |
ENTO closed down 1.74 percent on Wednesday, November 20, 2024, on 19 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% |
| Alert | Time |
|---|---|
| Possible NR7 | about 18 hours ago |
| 60 Minute Opening Range Breakout | about 22 hours ago |
| Up 2% | about 22 hours ago |
| Up 1% | about 22 hours ago |
| Down 5% | about 22 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Pharmacy Medication Gastrointestinal Disease Gastrointestinal Tract Covid 19
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Pharmacy Medication Gastrointestinal Disease Gastrointestinal Tract Covid 19
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 14.5 |
| 52 Week Low | 0.1873 |
| Average Volume | 450,527 |
| 200-Day Moving Average | 2.19 |
| 50-Day Moving Average | 0.50 |
| 20-Day Moving Average | 0.60 |
| 10-Day Moving Average | 0.55 |
| Average True Range | 0.08 |
| RSI (14) | 34.64 |
| ADX | 30.76 |
| +DI | 16.61 |
| -DI | 25.70 |
| Chandelier Exit (Long, 3 ATRs) | 0.50 |
| Chandelier Exit (Short, 3 ATRs) | 0.63 |
| Upper Bollinger Bands | 0.79 |
| Lower Bollinger Band | 0.41 |
| Percent B (%b) | -0.03 |
| BandWidth | 62.70 |
| MACD Line | -0.03 |
| MACD Signal Line | 0.01 |
| MACD Histogram | -0.0376 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.46 | ||||
| Resistance 3 (R3) | 0.46 | 0.44 | 0.45 | ||
| Resistance 2 (R2) | 0.44 | 0.43 | 0.44 | 0.45 | |
| Resistance 1 (R1) | 0.42 | 0.42 | 0.41 | 0.42 | 0.44 |
| Pivot Point | 0.40 | 0.40 | 0.40 | 0.40 | 0.40 |
| Support 1 (S1) | 0.38 | 0.39 | 0.37 | 0.38 | 0.36 |
| Support 2 (S2) | 0.36 | 0.38 | 0.36 | 0.35 | |
| Support 3 (S3) | 0.34 | 0.36 | 0.35 | ||
| Support 4 (S4) | 0.34 |
